Genetic-Guided Early Switch to Low-Potency Single Antiplatelet Therapy Versus High-Potency Therapy to Reduce Bleeding in High-Risk Patients After Acute Coronary Syndrome

What this Trial Is About

Researchers are evaluating treatments for patients who have experienced acute coronary syndrome ACS, focusing on reducing bleeding risks while maintaining protection against heart-related events. This phase 3 randomized trial compares two approaches a high-potency single antiplatelet therapy versus an early switch to a low-potency single antiplatelet therapy guided by genetic testing. The study addresses the challenge that potent medications like ticagrelor or prasugrel, while effective, can increase bleeding risk, which is linked to higher mortality in these patients. Participants are randomly assigned 1 to 3 months after their ACS event to either continue a high-potency antiplatelet therapy ticagrelor or prasugrel or switch to a low-potency antiplatelet therapy aspirin or clopidogrel based on their genetic profile for clopidogrel metabolism. The control group stops aspirin and continues with the potent antiplatelet, while the intervention group uses genetic testing to guide treatment choice. Stratification considers revascularization status, genotype, and center. The intervention uses bedside genetic testing with rapid results to determine the appropriate medication. Throughout the one-year follow-up, participants undergo monitoring for bleeding events and cardiovascular outcomes. Researchers assess the combined rate of major and minor bleeding as the primary outcome, alongside secondary measures like major adverse cardiovascular events and separate rates of major or minor bleeding. Safety and efficacy are tracked from randomization until one year later. Participants remain under regular clinical evaluation and provide informed consent, with their medical care supervised throughout the trial.

Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome